undamentalytics Newsletter
Sign in

Korro Bio, Inc. revenue

Korro Bio, Inc.'s revenue was $6.4m in fiscal 2025, up 181.5% on the year before. Since fiscal 2019 ($28.9m) it has grown at a compound -22.3% a year. Over the last twelve months it was $2.4m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue29371400262
Growth on the year before—+27.8%−62.0%−100.0%——+181.5%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Korro Bio, Inc. $2.4m -62.1% -53.7%
Collplant Biotechnologies Ltd $2.4m 360.4% —
Vistagen Therapeutics, Inc. $2.5m 287.3% —
Korsana Biosciences, Inc. $1.9m -12.6% —
Seres Therapeutics, Inc. $1.9m 100.0% -75.6%
Upstream Bio, Inc. $3.2m 16.0% —

Compare with peers

Head to head: CLGN vs KRROKRRO vs VTGNKRRO vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Korro Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Korro Bio, Inc.